H3B-6527
H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity[1].
Product Specifications
CAS Number
1702259-66-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/H3B-6527.html
Purity
98.0
Solubility
DMSO : 2.5 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)C)=C3)=O
Molecular Formula
C29H34Cl2N8O4
Molecular Weight
629.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Joshi JJ, et al. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven HepatocellularCarcinoma. Cancer Res. 2017 Dec 15;77 (24) :6999-7013.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP721404M 100 µg
SLC25A4 Human Recombinant Protein, Synthetic Nanodisc
Sign In for Pricing
View Details 
